Doceree Unveils Account-based Marketing Solution Tailored for Life Sciences Industry
Doceree ABM empowers healthcare marketers to reach institutional stakeholders and measure account lift.
Doceree, a global platform building solutions for HCP programmatic marketing with proprietary data tools, announced today the expansion of its targeting offering with Doceree ABMTM, an account-based marketing (ABM) solution built exclusively for healthcare and life sciences marketers that enables them to reach institutional decision makers based on accounts and intent.
Doceree ABMTM equips marketers to target specific accounts or employ intent-based data to recognize the interest of institutional stakeholders, whether it is a healthcare professional or an administrative decision maker. It will enhance the ability of marketers to communicate with qualified buyers that have demonstrated an interest in a product or a category at an account level and measure the account lift in real time.
“An ABM solution that’s developed to be used across a multitude of industries neglects the intricacies that are associated with pursuing high-value accounts in the life sciences sector,” says Harshit Jain MD, Founder & Global CEO, Doceree. “Our programmatic platform provides innovative ABM capabilities to target decision makers based on their behavior to elevate interactions brands have with priority accounts when an individual is actively seeking a solution.”
To begin with, Doceree has launched the solution in North America and plans to further roll it out to other global markets.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
